Revolutionizing Gene Therapy Delivery to the Retina

Returning in September as a digital event, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD, dry AMD, DME, IRDs and more.

Discover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics, Biogen, Gyroscope Therapeutics, Novartis, Horama and REGENXBIO

Join 150+ fellow industry attendees from discovery, preclinical and clinical backgrounds, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders.

Access the official agenda for more information.

Previous Gene Therapy for Ophthalmic Disorders Attendees Have Said:

“Very efficiently organized, excellent speakers.”

Chief Executive Officer - Eyevensys

“Very well organized and informative virtual conference!”

Senior Director, Regulatory Affairs - Adverum

“Well thought out agenda covering key hot topics with great participation.”

Vice President, Preclinical Development - Clearside Biomedical

What Will You Learn?

Gene Therapy Ophthalmic Disorders Favicon

The latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation

Gene Therapy Ophthalmic Disorders Favicon

How Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures

Gene Therapy Ophthalmic Disorders Favicon

Optogenetics and gene agnostic approaches from SparingVision, GenSight Biologics and Bionic Sight

Gene Therapy Ophthalmic Disorders Favicon

Clinical progress with different administration routes to the eye with clinical experience from REGENXBIO

Gene Therapy Ophthalmic Disorders Favicon

Key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing

Gene Therapy Ophthalmic Disorders Favicon

The realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics

Who Attended in 2020:

Gene Therapy Ophthalmic Disorders - Who Attended

Group Discounts Available:

Secure the best possible rates when you register as a group!

Gene Therapy Ophthalmic Disorders - Team Discount
  • 3 Passes - 10% Discount
  • 4 Passes - 15% Discount
  • 5+ Passes - 20% Discount

Proud to Partner With:

Other Events in the Gene Therapy Series